Daniel Bednarik is a Senior Consultant defining the funding and operations for a new immunotherapy approach that will be paradigm-changing and completely proprietary. Details of said project are pending closure of financing. . Daniel lives and works in Gemantown, Maryland.
Daniel Bednarik was previously the Director of Genomics and Bioinformatics for Cardiome Pharma Corporation. Prior to that role, Daniel Bednarik co-founded and was the Vice President of Cardiovascular Biology of Artesian Therapeutics, Inc., a company that was ultimately acquired by Cardiome in 2005.
After the acquisition, Daniel Bednarik was a consultant for Cardiome for two years and was hired by the company in 2007 due to his hard work and expertise in the field. Upon his hire, Daniel Bednarik helped to develop genomic and proteomic biomarker programs to aid in augmentation and acceleration of the design of the standard clinical trial. The main objective and interest of Cardiome Pharma was the creation and cultivation of the most expansive and recognized database of cardiovascular gene expression for Gene Logic.
Daniel Bednarik worked as a crucial scientist in the development of Human Genome Sciences’ (HGS) database. He has upwards of 28 years of experience in the field of virology with a focus on HIV and herpes virus pathophysiology. Daniel Bednarik was the co-recipient of a DARPA contract in 2006, which led to him and his colleagues creating and cultivation a completely unique non-host method for accelerated vaccine production and deployment. Daniel Bednarik is skilled and knowledgeable in developing and managing clinical programs. His education and training took place at the Temple University School of Medicine (Philadelphia) in 1985, and The Johns Hopkins University Oncology Center (Baltimore).
Personal Interest in the Field
Daniel Bednarik is extremely comfortable in both theory and application at the bench. To contribute to his strong basis of applicable knowledge, Daniel Bednarik has deeply rooted enthusiasm and curiosity about new technologies and biological discoveries. He strives to expand upon his knowledge base relevant to biotechnology, scientific discovery tools and the commercial and therapeutic opportunities they offer. While Daniel Bednarik is not a physician or physiologist, he enjoys actively seeking out, further understanding and integrating expert opinions in these areas of scientific study, among others that play a role in his field. He is a focused listener and a quick study, allowing him to absorb a great deal of knowledge. Daniel strongly believes that by investing in learning about other key areas of research, he is able to greatly expand his understanding of creative ideas for technical and experimental problem solving , as well as for identifying new targets for experimental inquiry and potential commercialization.
Daniel Bednarik is proactive and effective in cultivating interactions with industrial contacts that have ultimately proved to be highly beneficial programmatically to the laboratories of his collaborators in some form, and he strives to combine his background and knowledge to complement those of the organizations with which we he collaborates. Both the prior and current collaborative relationships Daniel Bednarik has generated remain grounded in mutual goals for discovery, shared benefit, and bilateral trust which stems from maintained and efficient professional interactions. As a result, Daniel Bednarik is thrilled to participate in ventures that utilize these professional relations, while simultaneously encompasing the efforts of both parties in forwarding their scientific/therapeutic goals.
Key Career Milestones
– Co-Founder of Artesian Therapeutics, Inc. Acquired by Cardiome Pharma, October, 2005. Helped to secure investment from Oxford Bioscience Partners $5M (2002); $500K from Dept. of Business & Economic Development, State of Maryland (2002).
– Secured $100K private investment from Brown Advisory Securities (Baltimore) for NX Pharmagen (2009).
Daniel Bednarik’s other experience areas:
-Recruitment of private capital,
-Clinical Program Development & Management,